NBTX VS IVVD Stock Comparison

Performance

NBTX
51/100

NBTX returned -7.36% in the last 12 months. Based on the other stocks in its sector with an average return of -7.41%, its performance is above average giving it a grade of 50 of 100.

IVVD
10/100

IVVD returned -57.71% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Sentiment

NBTX
63/100

NBTX had a bullish sentiment score of 63.40% across Twitter and StockTwits over the last 12 months. It had an average of 30.90 posts, 5.83 comments, and 30.90 likes per day.

IVVD

"Sentiment" not found for IVVD

Volatility

NBTX
20/100

NBTX has had a lower than average amount of volatility over the last 12 months giving it a grade of 20 of 100.

IVVD
45/100

IVVD has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

Technicals

NBTX

"Technicals" not found for NBTX

IVVD
21/100

IVVD receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

NBTX

"Earnings" not found for NBTX

IVVD
10/100

IVVD has missed earnings 5 times in the last 20 quarters.

Profit

NBTX

"Profit" not found for NBTX

IVVD
10/100

Out of the last 12 quarters, IVVD has had 0 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

Nanobiotix S.A. American Depositary Shares Summary

Nasdaq / NBTX

Healthcare

Biotechnology

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Invivyd, Inc. Common Stock Summary

Nasdaq / IVVD

Healthcare

Biotechnology

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Power up your portfolio